Search results for "MOE"

showing 10 items of 1101 documents

Chromoendoscopy in Inflammatory Bowel Disease

2012

Chromoendoscopy with methylene blue or indigo carmine significantly increases the diagnostic yield of finding intraepithelial neoplasia in patients with longstanding colitis. The number needed to treat is 14 for panchromoendoscopy to identify 1 additional patient with dysplasia. Chromoendoscopy can greatly facilitate the identification of flat lesions harboring intraepithelial neoplasia. Chromoendoscopy can guide biopsies and clearly reduces the amount of biopsies that are needed per patient. Magnifying endoscopy or CLE are additional techniques, which can be used in conjunction with chromoendoscopy to further reduce the amount of biopsies and to further increase the diagnostic yield. Chrom…

Adenomamedicine.medical_specialtyIntraepithelial neoplasiamedicine.diagnostic_testbusiness.industryfungiGastroenterologymedicine.diseaseGastroenterologyUlcerative colitisInflammatory bowel diseaseEndoscopy GastrointestinalEndoscopyChromoendoscopyDysplasiaInternal medicinePractice Guidelines as TopicEndomicroscopyHumansMedicineColitis UlcerativeColitisColorectal NeoplasmsColoring AgentsbusinessGastroenterology Clinics of North America
researchProduct

Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

2017

Abstract Background Transarterial chemoembolisation is the standard of care for intermediate stage (BCLC B) hepatocellular carcinoma, but it is challenging to decide when to repeat or stop treatment. Here we performed the first external validation of the SNACOR (tumour Size and Number, baseline Alpha-fetoprotein, Child-Pugh and Objective radiological Response) risk prediction model. Methods A total of 1030 patients with hepatocellular carcinoma underwent transarterial chemoembolisation at our tertiary referral centre from January 2000 to December 2016. We determined the following variables that were needed to calculate the SNACOR at baseline: tumour size and number, alpha-fetoprotein level,…

AdultAged 80 and overMaleCarcinoma HepatocellularHepatocellular carcinomaLiver Neoplasms610 MedizinKaplan-Meier EstimateSNACORMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Magnetic Resonance ImagingTreatment OutcomeTransarterial chemoembolisation610 Medical sciencesBiomarkers TumorHumansFemaleChemoembolization TherapeuticTomography X-Ray ComputedAgedNeoplasm StagingResearch Article
researchProduct

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as …

2005

The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A …

AdultCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentUrologyBreast NeoplasmsDisease-Free SurvivalDrug Administration Schedulebreast cancerchemoendocrine treatmentAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineAdjuvant therapyHumansDoxorubicinCyclophosphamideanthracyclinesGynecologyChemotherapypremenopausalbusiness.industryGoserelinadjuvant therapyMiddle AgedCombined Modality TherapyTamoxifenRegimenMethotrexateOncologyChemotherapy AdjuvantDoxorubicinFluorouracilLymphatic MetastasisGoserelinFemaleFluorouracilbusinessTamoxifenFollow-Up Studiesmedicine.drugBritish Journal of Cancer
researchProduct

Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial …

2019

Hepatocellular carcinoma (HCC) is one of the most common human malignancies, the incidence of which is growing worldwide. The prognosis of HCC is very poor and it is often accompanied by a high rate of recurrence. Conventional chemotherapeutic approaches are largely inefficient. In order to develop novel effective methods for the early detection and prognosis of HCC, novel markers and therapeutic targets are urgently required. The present study focused on the effects of the expression of the tumor suppressor gene insulin‑like growth factor‑2 receptor (IGF2R) on patient survival and tumor recurrence in patients with HCC; this study paid specific attention to the influence of transarterial ch…

AdultLiver CirrhosisMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularCirrhosisTumor suppressor geneKaplan-Meier EstimatePolymorphism Single NucleotideDisease-Free SurvivalReceptor IGF Type 203 medical and health sciences0302 clinical medicineInternal medicinemedicineCarcinomaHumansGenetic Predisposition to DiseaseChemoembolization TherapeuticAgedAged 80 and overOncogenebusiness.industryLiver NeoplasmsCase-control studyCancerGeneral MedicineMiddle AgedPrognosismedicine.diseaseMolecular medicinedigestive system diseases030104 developmental biologyOncologyCase-Control Studies030220 oncology & carcinogenesisHepatocellular carcinomaFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesOncology Reports
researchProduct

Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma

2013

Abstract Background Transarterial chemoembolisation (TACE) is an effective treatment for unresectable hepatocellular carcinoma (HCC), but can cause severe toxicity. Aim To identify predictive factors of severe TACE-related toxicity in patients with unresectable HCC. Methods All HCC patients who underwent TACE at the Dijon University Hospital between 2008 and 2011 were included in this retrospective study. Severe TACE-related toxicity was defined as the occurrence of any adverse event grade ≥4, or any adverse event that caused a prolongation of hospitalisation of >8 days, or any additional hospitalisation within 1 month after TACE. Factors predicting toxicity were identified using a logistic…

AdultLiver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularMultivariate analysisLogistic regressionGastroenterologyCohort StudiesHepatitis B ChronicLiver Cirrhosis AlcoholicRisk FactorsInternal medicinemedicineHumansIn patientAspartate AminotransferasesChemoembolization TherapeuticAdverse effectAgedRetrospective StudiesAged 80 and overHepatologybusiness.industryLiver NeoplasmsGastroenterologyRetrospective cohort studyAcute Kidney InjuryHepatitis C ChronicLiver Failure AcuteMiddle Agedmedicine.diseaseUniversity hospitalTumor BurdenSurgeryLogistic ModelsTreatment OutcomeDoxorubicinHepatic EncephalopathyHepatocellular carcinomaMultivariate AnalysisToxicityFemaleChemical and Drug Induced Liver InjuryIdarubicinbusinessDigestive and Liver Disease
researchProduct

Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience.

2012

Abstract Aims The aim of this study is to evaluate factors associated with the outcome after surgical resection and to compare the efficacy of surgery to transarterial chemoembolisation (TACE) in patients with advanced intrahepatic cholangiocarcinoma (IHC). Materials and methods 273 patients with IHC treated in our department between 1997 and 2012 were included in our study. Patients were divided according to therapy into surgical ( n  = 130), TACE ( n  = 32), and systemic chemotherapy/best supportive care ( n  = 111) groups. Clinicopathological characteristics and survival were reviewed retrospectively. Results The 1-, 3-, and 5-year survival rates in patients after surgical resection were…

AdultLiver CirrhosisMalemedicine.medical_specialtyKaplan-Meier EstimateSingle CenterCholangiocarcinomaHepatic ArteryAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansChemoembolization TherapeuticLymph nodeIntrahepatic CholangiocarcinomaAgedRetrospective StudiesAged 80 and overUnivariate analysisAnalysis of Variancebusiness.industryBile ductLiver NeoplasmsRetrospective cohort studyGeneral MedicineMiddle AgedSurgerymedicine.anatomical_structureBile Ducts IntrahepaticTreatment OutcomeOncologyBile Duct NeoplasmsChemotherapy AdjuvantResection marginSurgeryFemalePositive Surgical MarginbusinessEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II …

2019

Abstract Background Hepatic arterial embolisation therapy (HAET) is a treatment of liver metastases of gastrointestinal neuroendocrine tumours (GI-NETs). HAET increases circulating vascular endothelial growth factor levels. Everolimus is a treatment in NETs that may have antiangiogenic activity. Methods This phase II study was conducted in patients with predominant and progressive liver metastases from GI-NETs. Everolimus was initiated 7–30 days after HAET. The hypothesis was that everolimus after HAET would increase hepatic progression-free survival (hPFS) rate at 24 months from 35% to 50%. Results Among the 74 patients included, 88% had small-bowel primary tumour, 43% had grade I and 57% …

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyLung NeoplasmsPhases of clinical researchAntineoplastic AgentsBone NeoplasmsGastroenterologyStreptozocin03 medical and health scienceschemistry.chemical_compoundHepatic Artery0302 clinical medicineInternal medicineMucositisHumansMedicineIn patientEverolimusChemoembolization TherapeuticTrial registrationPeritoneal NeoplasmsAgedGastrointestinal NeoplasmsAged 80 and overGastrointestinal tractAntibiotics AntineoplasticEverolimusbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseaseEmbolization TherapeuticProgression-Free SurvivalConfidence intervalVascular endothelial growth factorNeuroendocrine Tumors030104 developmental biologyOncologychemistryDoxorubicin030220 oncology & carcinogenesisFemaleLymph Nodesbusinessmedicine.drugEuropean Journal of Cancer
researchProduct

Value of chromoendoscopy and magnification endoscopy in the evaluation of duodenal abnormalities: a prospective, randomized comparison.

2003

Background and study aims Endoscopic staining methods are increasingly being used to evaluate lesions in the esophagus and colon. The aim of this prospective study was to investigate chromoendoscopy and magnification endoscopy for the evaluation of mucosal lesions in the duodenum. Patients and methods Consecutive patients were randomly assigned to undergo conventional endoscopy without staining (group A) or intravital staining of the duodenal mucosa with indigo carmine and evaluation with a conventional video endoscope (group B) or a magnification endoscope (group C). Visible lesions were characterized before and after staining, and biopsies were taken for histological assessment. Results A…

AdultMalePathologymedicine.medical_specialtyEndoscopeAdolescentMagnificationIndigo CarmineChromoendoscopyDuodenal bulbmedicineHumansEsophagusDuodenal DiseasesIntestinal MucosaColoring AgentsDuodenoscopyAgedmedicine.diagnostic_testStaining and Labelingbusiness.industryGastroenterologyMiddle AgedEndoscopyStainingmedicine.anatomical_structureDuodenumFemalebusinessEndoscopy
researchProduct

High definition plus colonoscopy combined with i-scan tone enhancement vs. high definition colonoscopy for colorectal neoplasia: A randomized trial

2014

High definition endoscopy is the accepted standard in colonoscopy. However, an important problem is missed polyps.Our objective was to assess the additional adenoma detection rate between high definition colonoscopy with tone enhancement (digital chromoendoscopy) vs. white light high definition colonoscopy.In this prospective randomized trial patients were included to undergo a tandem colonoscopy. The first exam was a white light colonoscopy with removal of all visualized polyps. The second examination was randomly assigned in a 1:1 ratio as either again white light colonoscopy (Group A) or colonoscopy with tone enhancement (Group B). Primary endpoint was the adenoma detection rate during t…

AdultMalemedicine.medical_specialtyAdenomaColonoscopyAdenocarcinomaSensitivity and SpecificityGastroenterologyStatistics Nonparametriclaw.inventionChromoendoscopyHospitals UniversityRandomized controlled triallawGermanyInternal medicineImage Interpretation Computer-AssistedmedicineWhite lightClinical endpointHumansProspective StudiesAgedChi-Square DistributionHepatologymedicine.diagnostic_testbusiness.industryHigh definition endoscopyGastroenterologySignal Processing Computer-AssistedColonoscopyMiddle AgedImage Enhancementmedicine.diseaseLogistic ModelsHigh definitionFemaleRadiologyColorectal NeoplasmsbusinessDigestive and Liver Disease
researchProduct

Topical Voriconazole as Supplemental Treatment for Acanthamoeba Keratitis

2020

Purpose Voriconazole was shown to inhibit ergosterol synthesis in various acanthamoeba species. The purpose of this study was to evaluate the clinical outcome of treatment with supplemental topical voriconazole in patients with acanthamoeba keratitis (AK). Methods All patients who had been treated for AK with voriconazole 1% drops in conjunction with topical first-line antiacanthamoeba therapy composed of polyhexamethylene biguanide (PHMB) 0.02% and propamidine isethionate 0.1% (Brolene) between November 2014 and August 2017 at the Department of Ophthalmology, University Medical Center Mainz, were included. The main outcomes were treatment failure and recurrence rate. Secondary outcomes wer…

AdultMalemedicine.medical_specialtyAntifungal AgentsVisual acuitymedicine.drug_classAntiprotozoal AgentsVisual AcuityAcanthamoebaCorneaYoung Adult03 medical and health sciences0302 clinical medicinePharmacotherapymedicineAnimalsHumansIn patientEye Infections ParasiticAgedRetrospective StudiesAged 80 and overVoriconazoleDose-Response Relationship Drugbusiness.industryBiguanideRetrospective cohort studyMiddle AgedEye infectionmedicine.diseaseDermatologyBenzamidinesOphthalmologyAcanthamoeba KeratitisAcanthamoeba keratitis030221 ophthalmology & optometryDrug Therapy CombinationFemaleVoriconazoleOphthalmic Solutionsmedicine.symptombusiness030217 neurology & neurosurgeryFollow-Up Studiesmedicine.drugCornea
researchProduct